路易体病理对认知障碍患者的临床影响
该研究利用种子扩增技术检测883例记忆门诊轻度认知障碍或痴呆患者脑脊液中错误折叠的路易体相关α-突触核蛋白,23%存在路易体病理,其中仅21%在基线符合帕金森病或路易体痴呆临床标准,48%的路易体病理阳性患者合并阿尔茨海默病病理。路易体病理与幻觉及更差的注意力/执行、视空间和运动功能横断面相关,并与所有认知功能更快的纵向下降相关,独立于淀粉样蛋白β、tau、认知分期及路易体痴呆/帕金森病基线诊断。
要点
- 883例认知障碍患者中23%存在路易体病理,仅21%符合帕金森病或路易体痴呆临床标准。
- 路易体病理与幻觉及更差的注意力/执行、视空间和运动功能横断面相关。
- 路易体病理与所有认知功能更快的纵向下降相关,独立于阿尔茨海默病生物标志物。
核心结论
- 路易体病理状态提供了独立于阿尔茨海默病生物标志物和临床诊断的精准医学方法,用于预测认知障碍患者的临床轨迹,可能对认知障碍的临床管理及阿尔茨海默病和路易体药物试验设计有启示。
研究设计与样本
- 研究采用种子扩增技术分析BioFINDER研究中883例记忆门诊轻度认知障碍或痴呆患者脑脊液内错误折叠的路易体相关α-突触核蛋白。
主要发现
- 23%的患者存在路易体病理,其中仅21%在基线符合帕金森病或路易体痴呆临床标准。
- 路易体病理阳性患者中48%合并阿尔茨海默病病理;全样本中54%存在阿尔茨海默病病理,其中17%的轻度认知障碍和24%的痴呆患者同时路易体病理阳性。
- 横断面分析显示,路易体病理而非淀粉样蛋白β或tau与幻觉及更差的注意力/执行、视空间和运动功能相关。
- 路易体病理与所有受检认知功能更快的纵向下降相关,独立于淀粉样蛋白β、tau、认知分期及路易体痴呆/帕金森病基线诊断。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) pathology (amyloid-β and tau). Using a seed amplification assay, we analyzed cerebrospinal fluid for misfolded LB-associated α-synuclein in 883 memory clinic patients with mild cognitive impairment or dementia from the BioFINDER study. Twenty-three percent had LB pathology, of which only 21% fulfilled clinical criteria of Parkinson's disease or dementia with Lewy bodies at baseline. Among these LB-positive patients, 48% had AD pathology. Fifty-four percent had AD pathology in the whole sample (17% of mild cognitive impairment and 24% of patients with dementia were also LB-positive). When examining independent cross-sectional effects, LB pathology but not amyloid-β or tau, was associated with hallucinations and worse attention/executive, visuospatial and motor function. LB pathology was also associated with faster longitudinal decline in all examined cognitive functions, independent of amyloid-β, tau, cognitive stage and a baseline diagnosis of dementia with Lewy bodies/Parkinson's disease. LB status provides a better precision-medicine approach to predict clinical trajectories independent of AD biomarkers and a clinical diagnosis, which could have implications for the clinical management of cognitive impairment and the design of AD and LB drug trials.
引用
- Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023. PMID: 37464058. doi:10.1038/s41591-023-02449-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。